Lupus treatment typically involves a combination of medications tailored to how the disease affects your body. Nearly every lupus patient starts with hydroxychloroquine, and most will take at least one or two additional drugs depending on whether their lupus targets the joints, skin, kidneys, or other organs. The medications fall into a few broad categories: a foundational antimalarial, steroids for flares, immunosuppressants for organ protection, biologics for harder-to-control disease, and pain relievers used cautiously on the side.
Hydroxychloroquine: The Starting Point
Hydroxychloroquine is the closest thing lupus has to a universal medication. Originally developed to treat malaria, it dials down the overactive immune system in ways that reduce flares, protect organs from long-term damage, and even improve survival. Most rheumatologists prescribe it at diagnosis and recommend staying on it indefinitely, even when you feel well. The standard dose is kept at or below 5 mg per kilogram of your actual body weight per day.
The main long-term concern is the possibility of damage to the retina. You’ll typically get a baseline eye exam with specialized imaging shortly after starting the drug. If you don’t have risk factors like kidney disease, annual eye screenings can often be deferred for the first five years. After that, yearly screening becomes routine. Most people tolerate the drug well for decades without any eye problems, but catching early changes means you can stop the medication before any vision loss becomes permanent.
Steroids for Flares
Corticosteroids like prednisone are the fastest way to bring a lupus flare under control. They suppress inflammation broadly and can calm symptoms within days. For lupus nephritis (kidney involvement), current guidelines recommend starting at no more than 0.5 mg/kg/day of prednisone, capping at 40 mg daily, then tapering with a goal of getting to 5 mg per day or less within six months.
Tapering matters. A large multinational study found that gradually reducing steroids by small increments (around 1 mg at a time) did not increase the risk of flares, while staying on higher doses raised the likelihood of irreversible organ damage over time. The pattern in modern lupus care is clear: use steroids to put out the fire, then get off them as quickly as your disease allows. Your doctor will likely add or adjust other medications specifically so you can reduce your steroid dose.
Immunosuppressants for Organ Protection
When lupus threatens your kidneys, brain, blood cells, or other organs, immunosuppressant medications become essential. These drugs hold back the immune system more aggressively than hydroxychloroquine alone. Which one you take depends largely on what part of your body is involved.
Mycophenolate mofetil is one of the most commonly prescribed options, particularly for lupus affecting the kidneys. It’s a cornerstone of most kidney-targeted treatment plans and appears in nearly every recommended combination regimen for lupus nephritis.
Methotrexate works best for joint pain and swelling, especially when multiple joints are involved. It’s less effective for serious organ involvement like kidney disease, so it tends to be used for lupus that primarily causes arthritis, rashes, or fatigue rather than internal organ damage.
Azathioprine is another option sometimes used for maintenance therapy or for patients who can’t tolerate mycophenolate. It has a long track record in lupus care and is one of the few immunosuppressants considered safer during pregnancy.
Biologics: Targeted Immune Therapy
Biologic medications are newer, lab-engineered drugs that block specific parts of the immune system rather than suppressing it broadly. Two are currently approved for lupus.
Belimumab (Benlysta) targets a protein that helps certain immune cells survive longer than they should. By reducing the number of these overactive cells, it lowers disease activity over time. It’s used alongside standard therapy and has become part of recommended combination regimens for lupus nephritis, where it’s paired with mycophenolate and a steroid.
Anifrolumab (Saphnelo) works differently. It blocks the receptor for type I interferons, a group of immune signaling molecules that are abnormally elevated in many lupus patients. This drug is approved for adults with moderate to severe lupus who are already on standard treatment. It’s given as an intravenous infusion every four weeks. One important limitation: it hasn’t been studied in patients with severe active kidney disease or central nervous system lupus, so it’s not recommended for those situations.
Combination Therapy for Kidney Disease
Lupus nephritis gets its own treatment approach because kidney damage can become permanent if not controlled. The American College of Rheumatology now recommends “triple therapy” rather than the older two-phase model of induction followed by maintenance. This shift reflects the idea that targeting multiple parts of the immune system simultaneously works better than escalating one drug at a time.
For the most common and serious forms of lupus nephritis (Class III and IV), recommended triple regimens include a steroid combined with one of three immunosuppressive pairs: mycophenolate plus belimumab, mycophenolate plus a calcineurin inhibitor, or low-dose cyclophosphamide plus belimumab. For another type of kidney involvement (Class V) with significant protein in the urine, the preferred combination is a steroid, mycophenolate, and a calcineurin inhibitor.
Voclosporin, approved in 2021, is one of these calcineurin inhibitors. In clinical trials, patients taking voclosporin were twice as likely to have a favorable kidney response compared to those who didn’t receive it. It’s always used alongside other medications, not on its own.
Treatments for Severe or Resistant Lupus
When lupus threatens critical organs or doesn’t respond to standard immunosuppressants, stronger options come into play. Cyclophosphamide is a potent chemotherapy-class drug reserved for serious situations like rapidly progressing kidney disease, severe lung inflammation, or nervous system involvement. It’s highly effective at inducing remission but carries significant side effects, including infection risk and potential effects on fertility.
Rituximab, which destroys a specific type of immune cell called B cells, is used in similar situations. Studies comparing the two in severe lupus flares have found both to be highly effective at inducing remission. Rituximab is often tried when other treatments have failed or when cyclophosphamide isn’t a good fit.
Pain Relief and NSAIDs
Over-the-counter anti-inflammatory drugs like ibuprofen and naproxen are commonly used for lupus-related joint pain and muscle aches. They help with symptoms but do nothing to control the underlying disease. More importantly, they carry real risks for lupus patients specifically. A study tracking organ damage over time found that chronic NSAID use was associated with a 66% increased risk of cardiovascular damage in people with lupus, likely related to blood pressure effects that compound the cardiovascular risk lupus already carries.
This doesn’t mean you can never take ibuprofen for a headache, but relying on NSAIDs regularly for lupus pain is something to discuss with your rheumatologist. In many cases, better control of the underlying disease with immunosuppressants or biologics reduces the need for daily pain relievers.
Vaccines and Infection Risk
Because many lupus medications suppress the immune system, vaccines require some planning. Inactivated vaccines (like flu shots, pneumococcal vaccines, and COVID-19 vaccines) are safe on immunosuppressive therapy, though they may produce a weaker response. You might need extra doses of certain vaccines to build adequate protection.
Live vaccines are a different story. These contain weakened but living organisms that could cause serious infections in someone whose immune system is suppressed. Whether you can safely receive a live vaccine depends on how immunosuppressed you are. People on high-dose steroids, cyclophosphamide, or biologics are generally advised to avoid them. If possible, getting live vaccines before starting immunosuppressive therapy is the safest approach. When that’s not an option, your rheumatologist and an immunization specialist can help weigh the risks for your specific situation.